Immix Biopharma’s NXC-201 Secures FDA Breakthrough Therapy Status for AL Amyloidosis
Immix Biopharma, Inc. has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for its investigational therapy, NXC-201, aimed at treating relapsed or refractory AL amyloidosis.
This designation is designed to expedite the development and review of treatments for serious conditions when early clinical data show a potential significant advantage over current therapies.
The FDA’s decision follows promising interim results from the Phase 2 NEXICART-2 trial, presented at the American Society of Hematology (ASH) Annual Meeting in December 2025.
NEXICART-2 is a multi-center study in the U.S., enrolling approximately 40 patients, and is structured to support future regulatory approval.
NXC-201 is a BCMA-targeted CAR-T therapy developed to reduce off-target immune activation while eliminating the plasma cells that produce toxic light chains.
The therapy has also earned Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations from the FDA, as well as Orphan Drug status from the European Medicines Agency.
